Pentadecanoic acid (C15:0) is a saturated odd-chain fatty acid found naturally in full-fat dairy products and ruminant fats. Unlike most dietary saturated fats, it has attracted scientific attention for a distinct set of proposed biological activities—chief among them, potential effects on inflammatory signaling. Researchers, primarily from the biotech company Epitracker, have suggested it may function as an essential fatty acid, though this classification has not been formally adopted by regulatory bodies or mainstream nutrition science.
Chronic inflammation underpins a wide spectrum of metabolic and degenerative diseases, and scientists are actively exploring whether specific dietary fatty acids can meaningfully influence inflammatory pathways. This article reviews the proposed anti-inflammatory mechanisms of C15:0 and evaluates the published evidence behind them. It is informational in nature and does not constitute medical advice; the FDA has not evaluated C15:0 for the treatment or prevention of any disease.
Key Takeaways
- C15:0 may modulate inflammation through partial PPAR-α/δ agonism, reducing NF-κB-driven cytokine expression—a mechanism supported primarily by cell and molecular data, not yet by large human trials [10].
- Odd-chain-rich C15:0 preparations attenuated LPS-induced inflammatory cytokine production in microglial cell cultures, providing direct in vitro mechanistic evidence [8].
- Gut bacteria such as Parabacteroides distasonis produce C15:0 when fermenting dietary inulin, connecting microbiome health, fiber intake, and C15:0 availability in a single pathway with observed anti-inflammatory effects in preclinical models [4].
- Observational lipidomics studies consistently associate fatty acid profiles—including odd-chain fatty acids—with inflammatory disease states, but these are correlations, not proof that C15:0 supplementation alters disease outcomes.
- The classification of C15:0 as an essential fatty acid and its proposed anti-inflammatory benefits remain hypotheses advanced mainly by industry-affiliated researchers; independent clinical trial validation is limited.
Structure and Biology: Why Odd-Chain Fatty Acids Are Different
C15:0 is a 15-carbon saturated fatty acid—an ‘odd-chain’ molecule, meaning it carries an odd rather than even number of carbons. This structural distinction matters biologically. Odd-chain fatty acids are metabolized differently from their even-chain counterparts: they are catabolized to yield propionyl-CoA rather than acetyl-CoA, which feeds into different mitochondrial and biosynthetic pathways. A 2024 mini-review in Biochimie noted that C15:0 is detectable at low but measurable concentrations in human serum and tissues, with levels strongly linked to dairy fat intake, though certain gut bacteria can also produce it endogenously [6].
At the cellular level, C15:0 is proposed to integrate into cell membranes, where its odd-chain structure may improve membrane stability and reduce fragility compared with even-chain saturated fats. A 2025 hypothesis paper in Cureus suggested that optimizing membrane lipid composition with C15:0 could reduce oxidative stress and inflammatory signaling at the membrane interface [12]. This framework remains theoretical and requires prospective clinical validation.
A 2025 review in the World Journal of Biological Chemistry provides a detailed map of the molecular and cellular mechanisms attributed to C15:0, including pathway interactions relevant to inflammation [10]. Taken together, the structural and mechanistic picture positions C15:0 as biologically distinct from even-chain saturated fats—though the magnitude and clinical relevance of those differences in humans are still being established.
PPAR Agonism: The Primary Proposed Anti-Inflammatory Mechanism
The most discussed mechanism by which C15:0 may reduce inflammation is through partial agonism of peroxisome proliferator-activated receptors, specifically PPAR-α and PPAR-δ. These nuclear receptors regulate genes involved in fatty acid oxidation, lipid metabolism, and inflammatory cytokine production. Activation of PPAR-α in particular is associated with suppression of NF-κB signaling—a master transcriptional regulator of pro-inflammatory gene expression—which in turn reduces the transcription of cytokines such as TNF-α and IL-6.
A 2023 paper in Nutrients, using cell-based assays, reported that C15:0 shares mechanistic activities with several recognized longevity-supporting compounds, including activities consistent with PPAR pathway engagement [5]. The authors positioned these findings as evidence for C15:0’s broad cellular relevance. It is important to note that the paper’s authors are affiliated with Epitracker Inc., which commercializes C15:0 supplements; independent replication of these specific cell-activity findings remains limited.
The 2025 World Journal of Biological Chemistry review elaborates on how PPAR engagement by C15:0 may cascade into reduced production of inflammatory mediators [10]. While this mechanistic account is plausible and consistent with known PPAR biology, translating cell-level receptor pharmacology into human anti-inflammatory outcomes requires evidence from well-designed clinical trials that are currently lacking.
Cell-Based Evidence: Cytokine Suppression in Inflammatory Models
Direct experimental support for C15:0’s anti-inflammatory potential comes from a 2025 study in International Immunopharmacology examining Pentadecyl®, an odd-chain-rich triglyceride mixture derived from Aurantiochytrium oil. In LPS-stimulated BV-2 microglial cells—a standard in vitro model for neuroinflammation—this odd-chain-rich preparation significantly attenuated the production of pro-inflammatory cytokines [8]. While the study used a multi-component mixture rather than pure C15:0, it provides cell-level mechanistic support for the anti-inflammatory hypothesis.
It is worth acknowledging the limits of in vitro evidence: cells in culture lack the metabolic complexity, tissue architecture, and systemic feedback loops of a living organism. Concentrations used in cell experiments often exceed what would be achievable through diet or standard supplementation. These findings are best understood as hypothesis-generating—they tell us C15:0-related compounds can engage anti-inflammatory pathways in cells, not that supplementation will produce comparable effects in people.
The Gut Microbiome Connection: C15:0 as a Microbial Metabolite
A compelling emerging line of evidence positions C15:0 not only as a dietary nutrient but as a product of gut microbial metabolism. A 2023 study in Nature Microbiology found that Parabacteroides distasonis, a beneficial gut bacterium, produces pentadecanoic acid when fermenting dietary inulin. This microbially generated C15:0 was associated with suppression of non-alcoholic steatohepatitis (NASH)—a condition with a prominent inflammatory and metabolic component—in preclinical models [4]. This finding links dietary fiber intake, gut microbiome composition, and C15:0 availability in a single pathway.
The broader principle—that gut-derived lipid metabolites shape immune responses—is reinforced by additional research. A 2019 study in Frontiers in Cellular and Infection Microbiology demonstrated that antibiotic-induced disruption of the gut microbiota substantially alters the local metabolome, including fatty acid profiles, and skews immune responses [3]. A 2025 paper in Gut Microbes showed that lipid molecules produced by Akkermansia muciniphila are dynamically regulated during colitis and modulate macrophage inflammatory behavior [11]—further evidence that microbiome-derived lipids serve as active immunomodulatory signals.
These findings suggest that C15:0’s relationship to inflammation is not reducible to direct receptor activation alone. Its production by commensal bacteria, and the dependence of that production on dietary fiber, positions it within the diet-microbiome-immune axis—a complex system where disruption at any point could influence inflammatory tone.
Observational Evidence: Fatty Acid Profiles and Inflammatory Disease
Several observational and lipidomic studies have examined fatty acid profiles in people with inflammatory conditions, providing indirect evidence about C15:0’s relevance. A 2017 lipidomics study in Scientific Reports found that serum and synovial fluid fatty acid profiles predicted obesity-associated osteoarthritis, synovitis, and wound repair outcomes, linking lipid composition tightly to joint inflammatory status [1]. A 2018 study in the British Journal of Nutrition found that serum fatty acid profiles tracked with progression from dengue fever to the more severe dengue hemorrhagic fever and shock syndrome, suggesting fatty acid status is a meaningful correlate of inflammatory disease severity [2].
In post-stroke neuroinflammation, a 2025 study in Biomolecules found that free fatty acid levels correlated with IL-1β and its receptor antagonist (IL-1RA) in the early subacute phase—two pivotal regulators of neuroinflammatory cascades [9]. A multi-omic analysis of hidradenitis suppurativa, a painful chronic inflammatory skin condition, identified fatty acid metabolism among the dysregulated pathways [7], raising the question of whether odd-chain fatty acid status is relevant in cutaneous inflammation. All of these are associative findings; they do not demonstrate that raising C15:0 levels through diet or supplementation would alter outcomes in these conditions.
What the Evidence Does and Does Not Support
The current evidence for C15:0 as an anti-inflammatory agent is mechanistically coherent but clinically premature. The PPAR agonism hypothesis is plausible given established receptor biology. Cell culture experiments show cytokine suppression [8]. Microbial production of C15:0 links it to gut-immune communication [4]. And population-level lipidomics consistently finds that fatty acid profiles—including odd-chain acids—track with inflammatory conditions [PMID 28317846, PMID 41301455]. Taken together, these lines of evidence constitute a reasonable mechanistic hypothesis.
What the evidence does not yet support is clinical efficacy. Randomized controlled trials in humans specifically examining C15:0’s effect on inflammatory biomarkers or inflammatory disease outcomes are limited. Much of the foundational work originates from or has been co-authored by Epitracker-affiliated researchers—a conflict of interest worth acknowledging even as it does not automatically invalidate the findings. The 2024 mini-review in Biochimie explicitly notes that the essentiality hypothesis and the broader clinical picture for C15:0 remain contested and awaiting independent confirmation [6].
Supplement doses studied in humans have generally ranged from 100 to 300 mg per day without serious adverse events, but optimal dosing for any anti-inflammatory benefit, if one exists, has not been established in clinical trials.
🛒 Where to Buy Pentadecanoic Acid (C15:0)
- Epitracker Fatty15 C15:0 Fatty Acid SupplementLab-tested / studied
capsules, 100 mg C15:0 per capsule; 1 capsule/day starter, 2 capsules/day maintenance — Category creator; the only C15:0 supplement backed by the original Epitracker research team (Venn-Watson et al.); uses a patented, sustainably-sourced pure C15:0 ingredient; most expensive per-capsule but reference product for all comparisons - Double Wood Supplements Pentadecanoic Acid C15:0
capsules, 200 mg C15:0 per serving (2 capsules) — One of the first genericized C15:0 supplements; significantly lower price than Fatty15; no independent clinical trials on this specific product; good option for budget-conscious buyers who want to trial the fatty acid - Sports Research Pentadecanoic Acid C15:0
softgels, 100 mg C15:0 per softgel — Established supplement brand with strong Amazon presence; third-party tested; softgel form may aid fat-soluble absorption; competitively priced mid-tier option - BulkSupplements Pentadecanoic Acid Powder (C15:0)
powder, 100–300 mg per measured serving — Most economical option for higher-dose protocols or stackers; requires a milligram-accurate scale; no excipients or additives; not recommended for beginners unfamiliar with powder dosing
As an Amazon Associate we earn from qualifying purchases. Shilajit quality varies widely — always choose a product with a published third-party heavy-metal test (COA) before buying.
A Note on the Evidence
The anti-inflammatory evidence for C15:0 consists primarily of cell culture data, animal models, and observational studies; large-scale, independent, randomized controlled trials in humans are lacking, and no regulatory body has validated therapeutic claims. Anyone considering C15:0 supplementation—especially those managing inflammatory conditions or taking medications—should consult a qualified healthcare provider before use.
Frequently Asked Questions
How does C15:0 reduce inflammation at the cellular level?
C15:0 is proposed to act as a partial agonist of PPAR-α and PPAR-δ, nuclear receptors that suppress NF-κB-driven inflammatory gene expression and reduce output of cytokines such as TNF-α and IL-6. In cell models, odd-chain-rich preparations have attenuated LPS-induced cytokine production in microglial cells [8]. The 2025 molecular mechanisms review in the World Journal of Biological Chemistry provides further detail on these proposed pathways [10], though human trial confirmation is limited.
Is gut microbiome health relevant to C15:0 levels and inflammation?
Yes. The bacterium Parabacteroides distasonis produces C15:0 as a byproduct of fermenting dietary inulin, and this pathway was associated with reduced liver inflammation in preclinical models [4]. Antibiotic-induced microbiome disruption alters the fatty acid metabolome and shifts immune responses [3], suggesting that microbiome composition influences how much C15:0 the body receives from both dietary and microbial sources.
Which inflammatory conditions has C15:0 been studied in?
Fatty acid profiles including odd-chain acids have been examined in osteoarthritis [1], dengue fever severity [2], post-stroke neuroinflammation [9], and hidradenitis suppurativa [7]. These are observational findings linking fatty acid status to inflammatory disease—they do not demonstrate that C15:0 supplementation treats or prevents any of these conditions.
Is the 'essential fatty acid' label for C15:0 scientifically established?
Not formally. The essentiality hypothesis—that the body cannot synthesize adequate C15:0 and must obtain it from diet—has been advanced primarily by Epitracker researchers and is discussed in a 2024 mini-review that notes it remains controversial and unconfirmed by major regulatory bodies [6]. The FDA and mainstream nutrition organizations have not adopted this classification.
How do C15:0's proposed anti-inflammatory properties compare to those of omega-3 fatty acids?
Omega-3 fatty acids (EPA and DHA) have a substantially larger independent clinical trial evidence base for anti-inflammatory effects than C15:0. Omega-3s primarily modulate eicosanoid pathways; C15:0 is proposed to work via PPAR agonism and membrane remodeling [5]. At this stage, the evidence for omega-3 anti-inflammatory effects is far more extensively replicated and clinically validated than for C15:0.
Are C15:0 supplements safe to take?
Published studies at doses of approximately 100–300 mg per day have not reported serious adverse events. However, long-term safety data from large, independent trials are not yet available. The FDA has not evaluated C15:0 supplements for safety or efficacy. Anyone who is pregnant, breastfeeding, taking immunomodulating or lipid-lowering medications, or managing a chronic inflammatory condition should consult a healthcare provider before adding C15:0 to their regimen.
References
- Wu CL et al. Serum and synovial fluid lipidomic profiles predict obesity-associated osteoarthritis, synovitis, and wound repair. Scientific reports (2017). PMID 28317846
- Villamor E et al. Serum fatty acids and progression from dengue fever to dengue haemorrhagic fever/dengue shock syndrome. The British journal of nutrition (2018). PMID 30105961
- Sun L et al. Antibiotic-Induced Disruption of Gut Microbiota Alters Local Metabolomes and Immune Responses. Frontiers in cellular and infection microbiology (2019). PMID 31069173
- Wei W et al. Parabacteroides distasonis uses dietary inulin to suppress NASH via its metabolite pentadecanoic acid. Nature microbiology (2023). PMID 37386075
- Venn-Watson S et al. Pentadecanoic Acid (C15:0), an Essential Fatty Acid, Shares Clinically Relevant Cell-Based Activities with Leading Longevity-Enhancing Compounds. Nutrients (2023). PMID 37960259
- Ciesielski V et al. New insights on pentadecanoic acid with special focus on its controversial essentiality: A mini-review. Biochimie (2024). PMID 39395658
- Garbayo-Salmons P et al. Hidradenitis Suppurativa from a Multi-Omic Scope. Journal of cutaneous medicine and surgery (2025). PMID 39487752
- Tsuruta K et al. Pentadecyl®, an odd-chain-rich triglyceride mixture derived from Aurantiochytrium oil, attenuates lipopolysaccharide-induced inflammatory cytokine production in BV-2 microglial cells. International immunopharmacology (2025). PMID 40349404
- Kotlega D et al. Free Fatty Acids Correlate with the Interleukin-1 β and Interleukin-1 Receptor Antagonist in the Early Subacute Phase of Stroke. Biomolecules (2025). PMID 41301455
- Mercola J et al. Molecular and cellular mechanisms of pentadecanoic acid. World journal of biological chemistry (2025). PMID 41378251
- Selmi H et al. Ornithine lipids from Akkermansia muciniphila are dynamically modulated in colitis and shape macrophage inflammatory responses. Gut microbes (2025). PMID 41399961
- Mercola J et al. Optimizing Membrane Composition With C15 and Choline: A Novel Hypothesis to Mitigate Cancer Risk. Cureus (2025). PMID 41583314
